Table 2.

Chemotherapy regimens for patients with non‐small cell lung cancer (n = 14)

Patient	First	Second	Third	Fourth	AE‐IPF
1	CBDCA + nab‐PTX	S‐1			−
2	CBDCA + nab‐PTX	CBDCA + S‐1†	VNR	S‐1 (rechallenge)‡	+
3	CBDCA + nab‐PTX				+
4	CBDCA + nab‐PTX				−
5	CBDCA + nab‐PTX	S‐1	Pembrolizumab		−
6	CBDCA + nab‐PTX				−
7	CBDCA + nab‐PTX	VNR	S‐1		−
8	CBDCA + nab‐PTX	S‐1†	VNR‡		+
9	CBDCA + S‐1	CBDCA + nab‐PTX†	S‐1 (rechallenge)		−
10	CBDCA + S‐1	CBDCA + nab‐PTX			+
11	CBDCA + S‐1	CBDCA + nab‐PTX			−
12	CBDCA + S‐1	Pembrolizumab	nab‐PTX†		−
13	CBDCA + S‐1	Nivolumab	CBDCA + nab‐PTX		−
14	CBDCA + S‐1	nab‐PTX	Pembrolizumab		−

^†Treatment regimens discontinued due to adverse reactions other than AE‐IPF.

^‡Treatment regimens induced chemotherapy‐associated AE‐IPF.

+ and −, Presence and absence of AE‐IPF until death, respectively.

CBDCA, carboplatin; AE‐IPF, acute exacerbation of idiopathic pulmonary fibrosis; nab‐PTX, nanoparticle albumin‐bound PTX; PTX, paclitaxel; VNR, vinorelbine.